Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 5/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CCKBR | P32239 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27256861 | 0.84 | CYP1A2 (0.44) | CYP2C9CYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL27469804 | 0.81 | CYP2C9 (0.44) | CYP2C9CYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL17275494 | 0.81 | HPGD (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4239694 | 0.81 | HPGD (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL18205164 | 0.80 | CYP2D6 (0.46) | CYP2C9CYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL5552024 | 0.79 | MMP1 (0.41) | ALDH1A1 | |
| SCHEMBL27469778 | 0.79 | CYP1A2 (0.43) | CYP2C9CYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL27269528 | 0.79 | CYP1A2 (0.43) | CYP2C9CYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL18212467 | 0.79 | CYP1A2 (0.43) | CYP2C9CYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL22979670 | 0.78 | HSD17B10 (0.45) | CYP1A2CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085852-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20190202795-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2019-07-04 | — | — | US | disclosed |
| US-10053434-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20160326124-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202795-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | CYP2C9 3154/4885CYP1A2 2659/4885CYP2D6 3895/4885 |
| US-10053434-B2 | Histone deacetylase inhibitors and compositions and methods of use thereof | HDAC1, HDAC7, HDAC5 | CYP2C9 3154/4885CYP1A2 2659/4885CYP2D6 3895/4885 |
| US-20160326124-A1 | HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | HDAC1, HDAC7, HDAC5 | CYP2C9 3154/4885CYP1A2 2659/4885CYP2D6 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.